Recent Updates
Recently added Catalysts
QDEL Positive Sentiment

QuidelOrtho geht strategische Liefervereinbarung zur Erweiterung des globalen Immunoassay-Portfolios ein QuidelOrtho ist mit Lifotronic Technology Co., Ltd. eine langfristige strategische Liefervereinbarung eingegangen (Lifotronic Technology Co., Ltd.,...

Monday, February 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. This partnership aims to expand QuidelOrtho's global immunoassay portfolio and enhance customer access to scalable, high-quality, and cost-effective solutions in selected international markets outside the United States.
Price reaction · baseline $23.58 (2026-02-13 close) · 2 other QDEL headline(s) in the window, move may be shared
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic partnership enhances QuidelOrtho's global reach.
  • New platforms will improve customer access to assays.
  • Focus on scalable and cost-effective solutions.

Full Press Release Details

Vereinbarung fügt neue Analyseplattformen hinzu und erweitert das Assay-Menü in wichtigen internationalen Märkten
SAN DIEGO , 16. Februar 2026 /PRNewswire/ -- QuidelOrtho ist mit Lifotronic Technology Co., Ltd. eine langfristige strategische Liefervereinbarung eingegangen (Lifotronic Technology Co., Ltd., Aktienkürzel: 688389), um das globale Immunoassay-Portfolio von QuidelOrtho zu erweitern und den Zugang von Kunden zu skalierbaren, hochwertigen und kosteneffizienten Lösungen in ausgewählten Märkten außerhalb der Vereinigten Staaten zu beschleunigen.

Frequently Asked Questions

What is the purpose of the QuidelOrtho and Lifotronic agreement?

The agreement aims to expand QuidelOrtho's global immunoassay portfolio and improve customer access.

When was the strategic agreement announced?

The strategic agreement was announced on February 16, 2026.

What markets will benefit from this partnership?

The partnership will enhance access in selected international markets outside the United States.

What type of solutions will be offered through this agreement?

The agreement focuses on scalable, high-quality, and cost-effective solutions.

ShareAdd on Google
Tags: QDEL Viatris Investor Conferences Healthcare QuidelOrtho Lifotronic Technology immunoassay global expansion strategic partnership
Last updated: Feb 16, 2026

Biotech snapshot

Cash runway
$123M liquidity · $7M/mo burn
~17 mo
Low dilution risk